EpiBiologics Begins Phase 1 Trial of EPI-326 Bispecific Antibody for EGFR-Driven Cancers

Key Takeaways

• EpiBiologics has dosed the first patient with EPI-326, a novel bispecific antibody that degrades all forms of EGFR in cancer cells
• The Phase 1 study targets patients with advanced non-small cell lung cancer and head and neck squamous cell carcinoma
• EPI-326’s tissue-selective approach may offer improved safety compared to traditional EGFR-targeting therapies

---

SAN MATEO, Calif. — EpiBiologics announced today that it has dosed the first patient in its global Phase 1 clinical trial evaluating EPI-326, a tissue-selective bispecific antibody designed to treat EGFR-driven solid tumors.

Revolutionary EGFR Degradation Approach

EPI-326 represents a breakthrough in cancer treatment by targeting extracellular protein degradation. Unlike traditional EGFR inhibitors that block the receptor’s activity, this bispecific antibody degrades both oncogenic mutant and wild-type forms of EGFR directly in tumor tissue.

The company, which specializes in tissue-selective extracellular protein degradation, designed EPI-326 to overcome resistance mechanisms that limit current EGFR-targeted therapies. This approach could potentially address treatment failures seen with existing tyrosine kinase inhibitors.

Clinical Trial Details

The first-in-human study is evaluating EPI-326 in patients with advanced non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma. These cancer types frequently harbor EGFR mutations or overexpression, making them ideal targets for this novel therapeutic approach.

The Phase 1 trial will primarily assess safety, tolerability, and determine the optimal dosing regimen for EPI-326. Secondary endpoints include preliminary efficacy signals and pharmacokinetic profiles.

Market Implications

EGFR-targeted therapies represent a multi-billion dollar market, with drugs like Tagrisso (osimertinib) generating significant revenue for AstraZeneca. However, resistance development remains a major clinical challenge, creating opportunities for innovative approaches like EPI-326.

The tissue-selective degradation mechanism could potentially offer improved safety profiles compared to systemic EGFR inhibition, which often causes skin toxicity and diarrhea. If successful, EPI-326 could establish EpiBiologics as a leader in the emerging protein degradation field.

Looking Ahead

Initial safety and tolerability data from the Phase 1 study are expected in the coming months. Positive results could accelerate development timelines and attract potential partnership opportunities with larger pharmaceutical companies seeking novel oncology assets.

---

Frequently Asked Questions

What makes EPI-326 different from existing EGFR treatments?

EPI-326 degrades EGFR proteins rather than just blocking them, and uses tissue-selective targeting to potentially reduce side effects while overcoming resistance mechanisms that limit current therapies.

When will EPI-326 be available to patients?

EPI-326 is currently in Phase 1 trials. If successful, it would need to complete Phase 2 and 3 studies before potential FDA approval, which typically takes several years.

Which patients are eligible for the EPI-326 trial?

The Phase 1 study is enrolling patients with advanced non-small cell lung cancer and head and neck squamous cell carcinoma who have EGFR-driven tumors.